Company Encyclopedia
View More
name
Gilead Sciences
GILD.US
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc.
1.945 T
GILD.USMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking53/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE40.53%A
    • Profit Margin27.88%A
    • Gross Margin79.80%A
  • Growth ScoreB
    • Revenue YoY2.78%C
    • Net Profit YoY6336.51%A
    • Total Assets YoY7.35%B
    • Net Assets YoY16.67%A
  • Cash ScoreC
    • Cash Flow Margin358.66%C
    • OCF YoY2.78%C
  • Operating ScoreC
    • Turnover0.51C
  • Debt ScoreD
    • Gearing Ratio63.34%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Gilead Sciences to acquire Repare’s RP-3467

    Gilead Sciences has agreed to acquire Repare Therapeutics' Polθ ATPase inhibitor, RP-3467, for up to $30 million. The deal includes a $25 million upfront payment and up to $5 million upon technology transfer completion. This acquisition boosts Repare's cash reserves, impacting shareholder payments, estimated at $2.20 per share. Repare's CEO, Steve Forte, highlights the transaction as a significant portfolio move, combining Gilead's oncology expertise with RP-3467's potential in targeting BRCA mutations.

    Pharmaceutical Technology·
    US
    RPTX
    +0.78%
    US
    GILD
    -0.37%
    Pharmaceutical Technology·
    US
    RPTX
    +0.78%
    US
    GILD
    -0.37%

    Repare Therapeutics Inc. (RPTX) stock price rose over 20% to $2.66, reaching a one-year high. The company announced the sale of its polymerase ATPase inhibitor RP-3467 to Gilead Sciences for $30 million

    Wallstreetcn·
    US
    GILD
    -0.37%
    Wallstreetcn·
    US
    GILD
    -0.37%

    Gilead buys Repare Therapeutics cancer asset RP-3467 for $30 million, aims to enhance oncology research.

    Gilead Sciences Inc. (NASDAQ: GILD) has agreed to purchase Repare Therapeutics Inc.'s (NASDAQ: RPTX) polymerase theta (Polθ) ATPase inhibitor, RP-3467. The drug is currently in the POLAR Phase 1 trial, studying its safety, pharmacokinetics, pharmacodynamics, and preliminary activity either alone or combined with olaparib in adults with various cancers. Gilead emphasized their expertise in oncology research and development coupled with RP-3467's potential as a top Polθ ATPase inhibitor. Detailed information can be found on Benzinga.com.

    Unusual Whales·
    US
    GILD
    -0.37%
    US
    RPTX
    +0.78%
    Unusual Whales·
    US
    GILD
    -0.37%
    US
    RPTX
    +0.78%

    Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration | RPTX Stock News

    Repare Therapeutics announced the acquisition of its Polθ ATPase inhibitor, RP-3467, by Gilead Sciences for up to $30 million. The deal includes a $25 million upfront payment and a $5 million payment upon technology transfer completion. Additionally, Repare entered an arrangement agreement with XenoTherapeutics for the acquisition of all its common shares, with shareholders receiving approximately $2.20 per share based on the revised cash balance.

    StockTitan·
    US
    GILD
    -0.37%
    US
    RPTX
    +0.78%
    StockTitan·
    US
    GILD
    -0.37%
    US
    RPTX
    +0.78%

    Repare Therapeutics shares are trading higher after the company agreed to sell a cancer drug asset to Gilead Sciences for up to $30 million.

    benzinga_article·
    US
    GILD
    -0.37%
    benzinga_article·
    US
    GILD
    -0.37%
    © 2025 Longbridge｜Disclaimer